LEDGER STEVEN A 4
4 · Serina Therapeutics, Inc. · Filed May 27, 2026
Research Summary
AI-generated summary of this filing
Serina Therapeutics (SER) CEO Steven A. Ledger Receives 10,100-Share Award
What Happened
Steven A. Ledger, CEO of Serina Therapeutics (SER), was granted/acquired 10,100 shares on May 26, 2026. The filing reports a weighted-average acquisition price of $1.93 per share, for an aggregate value of approximately $19,493. This transaction is reported as an award/grant (transaction code A), an acquisition rather than a sale.
Key Details
- Transaction date: 2026-05-26; Form 4 filed: 2026-05-27 (timely).
- Reported price: weighted average $1.93 per share (range $1.87–$1.95 across multiple transactions; see footnote).
- Shares acquired: 10,100; aggregate value reported: $19,493.
- Shares owned after transaction: not disclosed in this filing.
- Footnote: the price is a weighted average of multiple purchase prices ($1.87–$1.95). Upon SEC request, the filer will provide the breakdown by price.
- No 10b5-1 plan, tax-withholding, or cashless exercise notation was reported.
Context
This was a stock award/grant to the CEO (an acquisition), which increases insider ownership but does not by itself indicate future performance. Because this is an award rather than a sale, many investors view it differently than routine disposition filings; however, no motives or future plans are disclosed.
Insider Transaction Report
- Award
Common Stock
[F1]2026-05-26$1.93/sh+10,100$19,493→ 10,100 total
Footnotes (1)
- [F1]The price reflects the weighted average purchase price of multiple transactions ranging from a low purchase price of $1.87 per share to a high purchase price of $1.95 per share. Upon the written request of the SEC, the Issuer or a security holder of the Issuer, the reporting person agrees to provide the number of shares sold at each price.